Sukses Engineering Sdn Bhd Suria - 29 Apr 2025 Form 3 Insider Report for Cyclacel Pharmaceuticals, Inc. (CYCC)

Reporting relationship: 10%+ Owner
Issuer ticker: CYCC
Reported as of: 29 Apr 2025
Net transaction value: $0
SEC form: 3
Accepted by SEC: 02 May 2025, 16:26:11 UTC
Prior SEC filing: 14 Jan 2025
Source filing: View source filing
Reporting owner signature: /s/ Chen Choon Seng

Key filing fact

Sukses Engineering Sdn Bhd Suria filed Form 3 for Cyclacel Pharmaceuticals, Inc. (CYCC) on 02 May 2025.

Key facts

This page summarizes Sukses Engineering Sdn Bhd Suria's Form 3 filing for Cyclacel Pharmaceuticals, Inc. (CYCC).
0 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 02 May 2025, 16:26.

Change

Previous filing in this sequence was filed on 14 Jan 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reporting Owners (1)

CIK 0002044793 Primary reporting owner

SURIA SUKSES ENGINEERING SDN BHD

Relationship: 10%+ Owner
Address: 26-13A STELLAR SUITES, JALAN, PUTERI 4/7, BANDAR PUTERI, PUCHONG SELANGOR,, MALAYSIA
Signature: /s/ Chen Choon Seng
Signature date: 02 May 2025

This filing has been restated. Open the amended filing.

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CYCC holding

Cyclacel Common Stock, par value $0.0001 per share

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 250,000
Date: 29 Apr 2025
Ownership: Direct

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

SEC remarks

Chen Choon Seng, the authorized representative of Suria Sukses Engineering Sdn. Bhd., has been deputized to represent the Reporting Person on the board of directors of the Issuer.